TipRanks
EPS Creative Health Technology Group Limited (HK:3860)
:3860
Hong Kong Market
Want to see HK:3860 full AI Analyst Report?

EPS Creative Health Technology Group Limited (3860) AI Stock Analysis

0 Followers

Top Page

HK:3860

EPS Creative Health Technology Group Limited

(3860)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - Gpt-5.6Sol)
Rating:51Neutral
Price Target:
HK$0.60
â–¼(-4.29% Downside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by uneven financial performance (return to net losses and volatile revenue), partially offset by improved balance-sheet leverage and a better 2026 cash-flow profile. Technicals add additional pressure with price below key moving averages and negative MACD, while valuation remains challenging due to losses (negative P/E) and only a modest dividend yield.
Positive Factors
Lower Leverage
Materially lower leverage reduces balance-sheet strain and improves financial flexibility. A sizable equity base gives the company greater capacity to absorb operating volatility, support ongoing operations, and pursue priorities without relying as heavily on debt financing.
Negative Factors
Revenue Volatility
The sharp swings in revenue make the company’s growth trajectory difficult to predict over the next several quarters. Uneven top-line performance can weaken operating leverage, complicate planning, and make it harder to sustain investment or build dependable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Lower Leverage
Materially lower leverage reduces balance-sheet strain and improves financial flexibility. A sizable equity base gives the company greater capacity to absorb operating volatility, support ongoing operations, and pursue priorities without relying as heavily on debt financing.
Read all positive factors

EPS Creative Health Technology Group Limited (3860) vs. iShares MSCI Hong Kong ETF (EWH)

EPS Creative Health Technology Group Limited Business Overview & Revenue Model

Company Description
EPS Creative Health Technology Group Limited functions as an investment holding company with diverse operations. It specializes in comprehensive apparel supply chain management, serving clients across Hong Kong, mainland China, Japan, the United S...
How the Company Makes Money
null...

EPS Creative Health Technology Group Limited Financial Statement Overview

Summary
Overall fundamentals are mixed. The balance sheet is a clear strength with materially reduced leverage and solid equity support (Balance Sheet Score 70). However, operating performance is unstable—revenue and profitability have been volatile with a return to a net loss in 2026 (Income Statement Score 42). Cash flow turned positive with solid free cash flow in 2026 (Cash Flow Score 55), but consistency and alignment with earnings remain concerns.
Income Statement
42
Neutral
Balance Sheet
70
Positive
Cash Flow
55
Neutral
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue457.65M544.52M644.62M452.91M519.95M
Gross Profit75.02M94.58M99.26M67.85M76.78M
EBITDA17.63M57.53M-2.96M-37.88M-14.53M
Net Income-13.85M38.59M-22.07M-45.74M-22.60M
Balance Sheet
Total Assets311.39M336.85M429.88M227.49M248.92M
Cash, Cash Equivalents and Short-Term Investments130.49M135.69M131.51M131.47M208.14M
Total Debt4.45M57.22M11.45M73.61M9.14M
Total Liabilities158.67M174.33M291.70M135.85M122.22M
Stockholders Equity105.91M120.68M65.36M87.64M131.32M
Cash Flow
Free Cash Flow25.11M-23.63M-33.60M-40.52M9.99M
Operating Cash Flow28.21M-17.92M-28.57M-38.11M10.05M
Investing Cash Flow-2.98M57.20M-20.40M-11.38M4.57M
Financing Cash Flow-37.51M-16.78M33.66M-27.75M98.11M

EPS Creative Health Technology Group Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.63
Price Trends
50DMA
0.59
Negative
100DMA
0.59
Negative
200DMA
0.60
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.70
Neutral
STOCH
68.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3860, the sentiment is Negative. The current price of 0.63 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.59, and above the 200-day MA of 0.60, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 68.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3860.

EPS Creative Health Technology Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$1.18T42.6120.26%0.79%11.14%19.43%
72
Outperform
HK$2.01B9.8710.15%10.52%-2.94%-6.03%
69
Neutral
HK$2.81B5.998.44%8.55%-4.39%-12.10%
68
Neutral
HK$9.51B6.3612.21%7.80%10.47%-8.83%
66
Neutral
HK$6.85B5.3613.22%22.96%-3.43%-0.67%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
51
Neutral
HK$337.81M-21.89-12.65%1.72%-15.95%-135.81%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3860
EPS Creative Health Technology Group Limited
0.58
-0.14
-19.44%
HK:0709
Giordano International
1.25
-0.10
-7.71%
HK:1368
Xtep International Holdings
3.53
-1.71
-32.63%
HK:3709
EEKA Fashion Holdings Limited
4.10
-3.29
-44.53%
HK:6110
Topsports International Holdings Limited
1.11
-1.48
-57.20%
HK:6288
Fast Retailing Co Ltd Shs Unsponsored Hong Kong Depositary Receipt Repr 1/100th Sh
36.84
8.84
31.57%

EPS Creative Health Technology Group Limited Corporate Events

EPS Creative Health Technology Faces Governance Gap After Independent Director Resigns
Oct 9, 2026
EPS Creative Health Technology Group Limited announced the resignation of independent non-executive director Mr. Choi Koon Ming, effective 9 October 2026, as he seeks to focus on other business commitments. His departure also ends his roles as cha...
EPS Creative Health Technology Updates Board and Committee Structure
Oct 9, 2026
EPS Creative Health Technology Group Limited has detailed the composition of its board of directors, naming six executive directors, one non-executive director and three independent non-executive directors. The leadership team spans core functions...
EPS Creative Health Issues Profit Warning on Rising Losses and Margin Pressure
Oct 2, 2026
EPS Creative Health Technology Group Limited has warned that it expects a higher loss after tax of about HK$8 million to HK$12 million for the six months ended 30 September 2026, compared with the same period a year earlier. The board attributes t...
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control
Sep 9, 2026
EPS Creative Health Technology Group Limited has announced that controlling shareholder EPS Holdings, Inc. has agreed to sell up to 130 million shares, or 22.32% of the company’s issued share capital, to Hong Kong‑based Wisdoms Group I...
EPS Creative Health Technology Wins Shareholder Approval for 2026 Framework Purchase Deal
Jul 31, 2026
Independent shareholders of EPS Creative Health Technology Group Limited have approved the 2026 Framework Purchase Agreement and its annual caps for the three financial years ending 31 March 2029. The resolution passed unanimously by poll at an ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2026